Psychedelics Drug Development Tracker

Psychedelics Drug Development Tracker

Developed by Michael Haichin, PharmD

Twitter
Linkedin

Mapping Drug Development in Psychedelics

This overview seeks to map out drug discovery & development activity in psychedelics. Drugs currently undergoing clinical trials are presented first, while drugs that are at the discovery or preclinical stage are catalogued in the latter half of this page.

Clicking on a company logo will present a brief summary of the related drug development activity, plus a link to the ClinicalTrials.gov entry for the relevant drug candidate, where available.

Due to the large amount of data presented on this page, we recommend you explore this resource on a desktop device. If you’re visiting this page on mobile, you may wish to email it to yourself to revisit when you’re on a device with a larger screen: click here to do so.

Those unfamiliar with the drug development and approval process may wish to review our Primer before continuing…

Discovery

The very first stage of the drug development process is the discovery of one or multiple suitable molecules that have therapeutic potential for improving certain diseases. The discovery process includes screening many molecules in the laboratory to identify those with desired properties before they are considered to be lead candidates that may progress to preclinical studies.

Preclinical

The preclinical stage involves lab and animal testing to identify one or more lead compounds and determine if they are safe for human testing.

Phase I

Phase I clinical trials are intended to establish initial safety in humans. The drug is given to a small number of healthy volunteers to test for possible side effects and determine what the safe dosing range is.

Phase II

Phase II clinical trials are the first in which the drug is tested in a small group of patient volunteers with the disease it is meant to treat. Phase II studies assess the safety and efficacy of the drug across a range of doses. Due to the small number of patients involved, conclusions about overall efficacy cannot be drawn, however Phase II trials provide guidance on how to optimally design larger Phase III trials to confirm the drug’s safety and efficacy.

Phase III

Phase III trials, also known as pivotal trials, demonstrate a drug’s safety and efficacy in a large group of patients. Typically, at least two successful Phase III trials are required in order to provide sufficient evidence of efficacy. Given the large number of patients required, Phase III trials are most often multi-centre, international trials.

Approval

At this stage, pharmaceutical companies can submit applications for drug approval. Regulatory authorities, such as the Food and Drug Administration (FDA) in the United States, review the data generated in all the studies (from preclinical to phase III), and after weighing the benefits and risk of the potential medicine, decide whether to grant approval.

Clinical Trials

The below companies are in the process of stewarding their drug candidates through clinical trials. Each drug and target indication are afforded their own row. As such, some companies and drugs appear more than once.

Following successful Phase III trials, a company may submit an application for drug approval. Regulators review data generated across all studies when deciding whether to grant approval. It can take up to 10 months for the FDA, for example, to approve a New Drug Application.

Reminder: click on logos to learn more about the drug under development.

Company

Indication

Phase I

Phase II

Phase III

MAPS

MAPS is currently conducting Phase 3 trials investigating MDMA-assisted psychotherapy as a potential treatment of post-traumatic stress disorder after receiving Breakthrough Therapy Status from the FDA. More details about MAPS's MDMA product, including previous trial results, can be found in their published Investigator's Brochure.

The first Phase III study (MAPP1) was deemed successful and is published here. The clinical trial registration linked below is of a second Phase III study (MAPP2).

ClinicalTrials.gov Identifier: NCT04077437

MAPS Logo

Post-traumatic stress disorder (PTSD)

MDMA
III

Compass Pathways

Compass Pathways' COMP360 is a psilocybin formulation currently being evaluated in a Phase II trial for potential use in treatment-resistant depression, after receiving Breakthrough Therapy Status from the FDA. The clinical trial registration linked below is of the ongoing Phase II study. COMP360 is also being evaluated in both preclinical and clinical (investigator-initiated) studies for numerous other indications.

ClinicalTrials.gov Identifier: NCT03775200

Company Profile

Compass Pathways logo colour

Treatment-resistant depression (TRD)

COMP360
II

Usona Institute

The Usona Institute is currently evaluating psilocybin-assisted therapy in a Phase II trial as a potential treatment for major depressive disorder, after receiving Breakthrough Therapy Status from the FDA. More details about Usona's psilocybin product, including Phase I results, can be found in their published Investigator's Brochure. The clinical trial registration linked below is of an ongoing Phase II study.

ClinicalTrials.gov Identifier: NCT03866174

Usona Institute logo

Major depressive disorder (MDD)

Psilocybin
II

MAPS

MAPS is evaluating MDMA-assisted psychotherapy as a potential treatment for eating disorders (anorexia nervosa and binge eating disorder). The clinical trial registration linked below is of an ongoing Phase II study.

ClinicalTrials.gov Identifier: NCT04454684

MAPS Logo

Eating disorders (anorexia nervosa and binge-eating disorder)

MDMA
II

MAPS

MAPS is evaluating MDMA-assisted psychotherapy as a potential treatment for anxiety associated with a life-threatening illness. The clinical trial registration linked below is of a completed Phase II study and the results can be found here.

ClinicalTrials.gov Identifier: NCT02427568

MAPS Logo

Anxiety associated with a life-threatening illness

MDMA
II

MAPS

MAPS is evaluating MDMA-assisted psychotherapy as a potential treatment for social anxiety in autistic adults. The clinical trial registration linked below is of a completed Phase II study and the results can be found here. 

ClinicalTrials.gov Identifier: NCT02008396

MAPS Logo

Social anxiety in autistic adults

MDMA
II

MindMed

MindMed is evaluating LSD-assisted therapy as a potential treatment for anxiety disorder. As part of a deal with University Hospital Basel's Liechti Lab, MindMed has acquired the rights to an ongoing Phase II trial. More details about that trial can be found in the clinical trial registration link below. A second Phase II trial is set to begin in 2021.

ClinicalTrials.gov Identifier: NCT03153579

Company Profile

MindMed Logo

Anxiety

LSD
II

MindMed

As part of a deal with University Hospital Basel's Liechti Lab, MindMed has acquired the rights to an ongoing Phase II evaluating LSD as a potential treatment for cluster headaches. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT03781128

Company Profile

MindMed Logo

Cluster headaches

LSD
II

Seelos Therapeutics

SLS-002 is an intranasal racemic ketamine product currently being evaluated in a Phase II trial as a potential treatment for acute suicidal ideation and behaviour (ASIB) in major depressive disorder. More details about the ongoing trial can be found in the clinical trial registration link below. 

ClinicalTrials.gov Identifier: NCT04669665

Seelos Therapeutics

Acute suicidal ideation and behaviour (ASIB) in major depressive disorder

SLS-002
II

Awakn Life Sciences

Awakn Life Sciences is set to evaluate MDMA-assisted psychotherapy in a Phase II trial as a potential treatment for Alcohol Use Disorder.

Awakn Life Sciences

Alcohol use disorder

MDMA
II

B.More

B.More is evaluating psilocybin-assisted therapy in a Phase II trial as a potential treatment for Alcohol Use Disorder. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT02061293

B.More

Alcohol use disorder

Psilocybin
II

Cybin

CYB001 is a sublingual film formulation of psilocybin and is set to be evaluated in a Phase II trial in 2021 as a potential treatment for Major Depressive Disorder.

Company Profile

Cybin

Major depressive disorder

CYB001
II

DemeRx

DMX-NB1 is a noribogaine formulation being investigated as a potential treatment of Opioid Use Disorder. Noribogaine is a long-acting metabolite of ibogaine.

DemeRx Logo

Opioid use disorder

DMX-NB1
II

Eleusis

ELE-Ket+ is a combination infusion therapy that includes ketamine. A Phase II study investigating ELE-Ket+ as a potential adjunctive treatment of major depressive disorder is set to begin in Q4 2021.

Company Profile

Eleusis Logo

Major depressive disorder (adjunctive treatment)

ELE-Ket+
II

Filament Health

PEX010 is a psilocybin formulation being developed by Filament Health and is set to be evaluated in a Phase II study as a potential treatment for major depressive disorder in 2021.

Filament Health invite

Major depressive disorder

PEX010
II

MAPS

MAPS is currently preparing a Phase II study to evaluate MDMA-facilitated cognitive behavioural conjoint therapy (CBCT) as a potential treatment for PTSD and relationship distress among couples in which one partner was diagnosed with PTSD. Results from an uncontrolled exploratory study can be found here.

MAPS Logo

CBCT for PTSD

MDMA
II

MindMed

MindMed is developing a microdosed LSD formulation that is set to be evaluated in a Phase II trial in collaboration with Maastricht University as a potential treatment for attention deficit hyperactivity disorder (ADHD) in adults.

Company Profile

MindMed Logo

Attention deficit hyperactivity disorder (ADHD)

LSD
II

MindMed

MindMed is developing LSD as a potential treatment of an undisclosed severe pain indication and is set to be evaluated in a Phase II study.

Company Profile

MindMed Logo

Undisclosed severe pain indication

LSD
II

Mydecine

Mydecine is developing a psilocybin product that is set to be evaluated in a Phase II trial as a potential treatment for post-traumatic stress disorder.

Company Profile

Mydecine Innovations logo

Post-traumatic stress disorder (PTSD)

Psilocybin
II

PharmaTher

PharmaTher is evaluating ketamine in a Phase II trial as a potential treatment for levodopa-induced dyskinesia in patients with Parkinson's disease.

Pharmather

Levodopa-induced dyskinesia in patients with Parkinson's disease

Ketamine
II

GH Research

GH001 is an inhaled formulation of 5-MeO-DMT, a short-acting psychedelic. A combined Phase I/II study investigating GH001 for potential use in treatment-resistant depression is ongoing. More details of this study can be found in the clinical trial registration link below. GH001 is also undergoing preclinical evaluation for two other unknown indications.

ClinicalTrials.gov Identifier: NCT04698603

GH Research

Treatment-resistant depression (TRD)

GH001
I / II

Small Pharma

SPL026 is an intravenous (IV) DMT formulation being developed by Small Pharma and is set to be evaluated in a combined Phase I/II study as a potential treatment for major depressive disorder. More details of this study can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04673383

Small Pharma Logo

Major depressive disorder (MDD)

SPL026
I / II

DemeRx

DMX-1002 is an ibogaine formulation set to be evaluated in a combined Phase I/II study as a potential treatment for Opioid Use Disorder (specifically for medically-assisted detoxification).

DemeRx Logo

Opioid use disorder

DMX-1002
I

Eleusis

ELE-LSD is a low-dose LSD product being developed as a potential treatment for Alzheimer's Disease. Previously reported Phase I trial results can be found here. A second Phase I trial is set to begin in Q4 2021.

Company Profile

Eleusis Logo

Alzheimer's Disease

ELE-LSD
I

MindMed

18-MC is a non-hallucinogenic ibogaine derivative intended for use in opioid withdrawal and as a potential treatment of opioid use disorder. 18-MC is currently being evaluated in a Phase I trial. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04292197

Company Profile

MindMed Logo

Opioid use disorder

18-MC
I

MindMed

As part of a deal with University Hospital Basel's Liechti Lab, MindMed is set to evaluate intravenous DMT in a Phase I trial in 2021. The intended indication(s) remains unclear. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04353024

Company Profile

MindMed Logo

Undisclosed

DMT
I

MindMed

MindMed is evaluating the combination of LSD and MDMA in a Phase I trial in collaboration with University Hospital Basel's Liechti Lab. The intended indication(s) remains unclear and more details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04516902

Company Profile

MindMed Logo

Undisclosed

MDMA+LSD
I

MindMed

MindMed is evaluating mescaline in a Phase I trial, though the intended indication(s) remains unclear. More details about the trial can be found in the clinical trial link below.

ClinicalTrials.gov Identifier: NCT04849013

Company Profile

MindMed Logo

Undisclosed

Mescaline
I

MindMed

MindMed is evaluating ketanserin, a 5-HT2A receptor antagonist, in a Phase I trial as a potential "LSD neutralizer" intended to shorten or stop the effects of an LSD session. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04558294

Company Profile

MindMed Logo
Ketanserin
I

Perception Neuroscience

PCN-101 is arketamine (or R-ketamine), a less dissociative isomer of ketamine, being developed for potential use in treatment-resistant depression. PCN-101 is currently being evaluated in a Phase I trial. More details about the Phase I trial can be found here.

Perception Neuroscience

Treatment-resistant depression (TRD)

PCN-101
I

Algernon Pharmaceuticals

AP-188 is a sub-hallucinogenic, intravenous DMT formulation being developed as a possible treatment of ischemic stroke and for post-stroke rehabilitation and is set to be evaluated in a Phase I trial in 2021.

Algernon Pharmaceuticals

Ischemic stroke and post-stroke rehabilitation

AP-188
I

Beckley Psytech

Beckley Psytech is developing a synthetic version of 5-MeO-DMT and will be evaluated in a Phase I trial in 2021.

Company Profile

Beckley Psytech Logo

Undisclosed

5-MeO-DMT
I

Beckley Psytech

Beckley Psytech is developing psilocybin as a potential treatment of short-lasting unilateral neuralgiform headache attacks (SUNHA) and will be evaluated in a Phase I trial in Q1 2021. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT04905121

Company Profile

Beckley Psytech Logo

Short-lasting unilaterial neuralgiform headache attacks (SUNHA)

Psilocybin
I

Ceruvia Lifesciences

NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of cluster headaches.

Ceruvia Lifesciences

Cluster headache

NYPRG-101
I

Ceruvia Lifesciences

NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in Phase I and is being evaluated as a potential treatment of migraines.

Ceruvia Lifesciences

Migraine

NYPRG-101
I

Ceruvia Lifesciences

SYNP-101 is a synthetic form of psilocybin being developed as a potential treatment for migraines. Previously reported Phase I results can be found here.

Ceruvia Lifesciences

Migraine

SYNP-101
I

Ceruvia Lifesciences

SYNP-101 is a synthetic form of psilocybin being developed as a potential treatment for cluster headaches. SYNP-101 is currently being evaluated in a Phase I trial. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT02981173

Ceruvia Lifesciences

Cluster headache

SYNP-101
I

Ceruvia Lifesciences

SYNP-101 is a synthetic form of psilocybin being developed as a potential treatment for obsessive compulsive disorder. SYNP-101 is currently being evaluated in a Phase I trial. More details about the trial can be found in the clinical trial registration link below.

ClinicalTrials.gov Identifier: NCT03356483

Ceruvia Lifesciences

Obsessive compulsive disorder

SYNP-101
I

Diamon Therapeutics

Diamond Therapeutics' lead programme is the development of low-dose psilocybin for the potential treatment of undisclosed anxiety disorders and is set to be evaluated in a Phase I trial in early 2021. Previously reported preclinical trial results can be found here.

Diamond Therapeutics

Anxiety

Psilocybin
I

Entheon Biomedical

Entheon Biomedical's lead programme is the development of intravenous (IV) DMT for the potential treatment of undisclosed substance use disorders and is set to be evaluated in a Phase I trial in Q3 2021.

Entheon Biomedical Logo

(Unspecified) Substance use disorder

DMT
I

Filament Health

PEX020 and PEX030 are formulations of a non-psilocybin mushroom compound being developed by Filament Health. Both will be evaluated and compared to PEX010, Filament's psilocybin product, in a Phase I trial in 2021.

Filament Health invite

Undisclosed

PEX020...
I

Journey Colab

Journey colab's lead programme is the development of synthetic mescaline for the potential treatment of alcohol use disorder and is set to be evaluated in a Phase I trial in 2021.

Journey Colab

Alcohol use disorder

Mescaline
I

Sacred Medicines

Sacred Medicines is currently developing a Phase I clinical trial to study ayahuasca tea in a group therapy setting.

Sacred Medicines

Undisclosed

Ayahuasca
I

Discovery & Preclinical

The very first stage of the drug development process is the discovery of one or multiple suitable molecules that have therapeutic potential for improving certain diseases. The discovery process includes screening many molecules in the laboratory to identify those with desired properties before they are considered to be lead candidates that may progress to preclinical studies.

The preclinical stage involves lab and animal testing to identify one or more lead compounds and determine if they are safe for human testing. If the lead compound(s) are found to be safe for human testing, clinical trials may commence.

Preclinical

CaaMTech

CaaMTech has a collaborative preclinical drug development program with the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program to help determine which of their compounds are the most promising to proceed to human trials. These include, but are not limited to:

  • Psilacetin (4-AcO-DMT), a prodrug of psilocin, the active metabolite of psilocybin;
  • 4-AcO-MET, 4-AcO-MALT, and 4-AcO-DALT, three psilacetin derivatives (source);
  • Deprocin (4-HO-DPT), a structural analogue of psilocin;
  • DMPT and DMALT (Source);
  • EPT and MALT, structural analogues of DMT (Source);
  • 5-MeO-DALT;
  • 5-MeO-DPT
  • Norpsilocin, another tryptamine found in psilocybin mushrooms (Source);
  • Miprocin (4-OH-MiPT);
  • 4-HO-TMT ("Amphoria"), the suspected active metabolite of aeruginascin, another tryptamine found in psilocybin mushrooms and 4-AcO-TMT ("Prophoria"), a prodrug of 4-HO-TMT (Source);
  • Bufotenidium (5-HTQ), also known as bufotenidine;
  • 2-5-Dimethylbufotenine (5-MeO-2-ME-DMT), a bufotenin derivative, and 2,5-dimethylbufotenidine (5-MeO-2-ME-TMT), a bufotenidine derivative (Source)

Company Profile

CaamTech Logo Colour
Various
Preclinical

Cybin

CYB003 is an orally dissolving tablet formulation of an unknown deuterated tryptamine molecule currently in the preclinical stage and is being evaluated as a potential therapy for alcohol use disorder.

CYB004 is an inhaled formulation of an unknown deuterated tryptamine molecule being evaluated as a potential therapy for both social and generalized anxiety disorders.

Company Profile

Cybin
CYB003/4
Preclinical

Eleusis

ELE-Psilo+ is a combination infusion therapy that includes psilocybin. A Phase I study investigating ELE-Psilo+ as a potential adjunctive treatment of major depressive disorder is set to begin in Q1 2022.

Company Profile

Eleusis Logo
ELE-Psilo+
Preclinical

Tryp Therapeutics

TRP-8802 is an orally-delivered synthetic psilocybin formulation currently in the preclinical stage, being evaluated as a potential treatment of fibromyalgia. Tryp is also considering other indications for TRP-8802, such as eating disorders (more specifically hyperphagia in the orphan disease Prader-Willi Syndrome), as well as other undisclosed neuropsychiatric disorders.

Company Profile

Tryp Therapeutics Logo 1
TRP-8802
Preclinical

Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals is a preclinical biotechnology company developing several psychedelic-related medicines including:

  • GM-300X, an ibogaine analogue intended as a potential treatment of opioid use disorder;
  • GM-200X, a non-hallucinogenic 5-HT2A agonist intended as a potential treatment for attention deficit hyperactivity disorder (ADHD);
  • a non-dissociative, oral arylcyclohexamine NMDA antagonist molecule, as a potential treatment for treatment-resistant depression.
Gilgamesh Pharmaceuticals logo
Various
Preclinical

Viridia Life Sciences

Viridia Life Sciences is in the preclinical stage of development of a DMT formulation. The intended indication(s) remains unclear.

Viridia Life Sciences
DMT
Preclinical

GH Research

GH002 is an injectable formulation of 5-MeO-DMT, a short-acting psychedelic. GH002 is currently in the preclinical stage for an unknown indication.

GH Research
GH002
Preclinical

Bexson Biomedical

BB-106 is a ketamine formulation delivered subcutaneously via a wearable medical pump. BB-106 is currently in the preclinical stage and is being evaluated as a potential treatment of depression, as well as a variety of pain-related indications including post-operative pain, cancer pain, and Complex Regional Pain Syndrome.

Bexson Biomedical
BB-106
Preclinical

Small Pharma

Small Pharma is in the preclinical stage of development of unknown deuterated tryptamine compounds.

Small Pharma Logo
Unkown
Preclinical

Field Trip

FT-104 is an unknown 5-HT2A agonist molecule currently in the preclinical stage of development. Field Trip anticipates initiating a Phase I study of FT-104 in 2021.

Company Profile

Field Trip logo
FT-104
Preclinical

Psilera Bioscience

Psilera Bioscience's drug pipeline or target indications are unclear thus far. The company is set to begin preclinical studies on a number psychedelic analogues in 2021 and may include novel DMT formulations.

Psilera Bioscience
Various
Preclinical

Delix Therapeutics

Delix Therapeutics is developing a number of non-hallucinogenic psychedelic compounds, referred to as psychoplastogens, and is currently in the preclinical stage of development. Details about one of Delix Therapeutics' lead compounds "DLX-7" or Tabernanthalog (TBG), a 5-MeO-DMT analog, were published here and here. Details about another compound, "DLX-1", also known as AAZ-A-154, were published here.

Delix Therapeutics
Various
Preclinical

Lophora

LPH-5 is unknown 5-HT2A agonist currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression. Lophora anticipates initiating a Phase I study of LPH-5 in 2022.

Lophora
LPH-5
Preclinical

Lobe Sciences

Lobe Sciences is currently in the preclinical stage of evaluating the combination of psilocybin and N-acetylcysteine (NAC) as a potential treatment of mild traumatic brain injury (mTBI) and/or post-traumatic stress disorder (PTSD).

Lobe Sciences Logo
Psilocybin + NAC
Preclinical

NeonMind

NeonMind is currently conducting a preclinical trial with psilocybin as a potential treatment for weight loss.

Neonmind logo
Psilocybin
Preclinical

Bright Minds Biosciences

Bright Minds has a number of 5-HT2C, 5-HT2A, and combined 5-HT2A + 5-HT2C agonist molecules in the preclinical stage of development. The 5-HT2C compounds are being evaluated for use in an undisclosed seizure disorder, opioid withdrawal, binge eating disorder, and Alzheimer's disease.

The 5-HT2A compounds are being evaluated for use in depression and post-traumatic stress disorder. The combined 5-HT2A + 5-HT2C compounds are being evaluated for use in an undisclosed chronic pain disorder. Bright Minds intends to progress three lead compounds (one from each category) to human studies in 2021.

Bright Minds Biosciences
Various
Preclinical

Alvarius

Alvarius is in the preclinical stage of developing 5-MeO-DMT as a potential treatment for cocaine use disorder.

Alvarius Placeholder
5-MeO-DMT
Preclinical

Usona Institute

The Usona Institute is in the preclinical stage of development of 5-MeO-DMT for an undisclosed indication. The synthesis and characterization of 5-MeO-DMT by Usona Institute chemists was recently published and can be found here. 

Usona Institute logo
5-MeO-DMT
Preclinical

Wesana Health

Wesana is in the preclinical stage of developing psilocybin as a potential treatment for traumatic brain injury (TBI).

Wesana Health
Psilocybin
Preclinical

BetterLife Pharma

TD-0148A is a non-hallucinogenic LSD derivative molecule, more commonly known as 2-Bromo-LSD or BOL-148. TD-1048A is currently in the preclinical stage and is being investigated for potential use in treatment-resistant depression, as well as migraines.

BetterLife Pharma
TD-0148A
Preclinical

Mydecine

Mydecine is currently in the preclinical stages of development for a number of compounds including:

  • MYCO-001, a psilocybin formulation from natural fungal sources;
  • MYCO-002, an unknown entactogen;
  • MYCO-003, an unknown psilocybin derivative;
  • MYCO-004, an unknown tryptamine compound intended to be delivered via skin patch.
Mydecine Innovations logo
Various
Preclinical

Revixia

RLS-01 is a formulation of Salvinorin A, a dissociative hallucinogen, currently in the preclinical stage of development and is being investigated for potential use in treatment-resistant depression.

Revixia Life Sciences
RLS-01
Preclinical

Ceruvia Lifesciences

NYPRG-101 is a non-hallucinogenic LSD analog, more commonly known as 2-Bromo-LSD or BOL-148. NYPRG-101 is currently in the preclinical stage and is being evaluated as a potential treatment of both opioid and alcohol use disorder.

Ceruvia Lifesciences
NYPRG-101
Preclinical

Discovery

Eleusis

Eleusis is developing an unknown 5-HT2A agonist molecule, intended for use as a potential treatment of peripheral inflammatory disease. Eleusis intends to select a lead candidate in Q4 2021.

Company Profile

Eleusis Logo
Discovery

EmpathBio

EmpathBio is developing an MDMA-derivative for use in entactogen-assisted psychotherapy to treat post-traumatic stress disorder. EmpathBio is currently in the lead selection stage of discovery.

EmpathBio Logo
Discovery

Tactogen

Tactogen has synthesized and is currently screening an initial group of ~25 entactogen molecules. Tactogen intends to select a lead compound to advance to preclinical studies by Q4 2021.

Tactogen
Discovery

CaaMTech

CaaMTech is a drug discovery company that aims to synthesize and characterize old and novel tryptamine compounds as well as optimize their various formulations. Their portfolio (see above for a partial list of published compounds) then undergoes preclinical assessment as part of a collaborative preclinical drug development program with the Designer Drug Research Unit at the National Institute on Drug Abuse Intramural Research Program.

Company Profile

CaamTech Logo Colour
Discovery

Cybin

Cybin's portfolio contains unknown phenethylamine and deuterated tryptamine compounds from Adelia Therapeutics, which are currently in the discovery stages for potential use in undisclosed psychiatric conditions.

Company Profile

Cybin
Discovery

Mindset Pharma

Mindset Pharma has synthesized and is currently screening 50 5-HT2A agonist molecules. Mindset intends to select a group of lead compounds to advance to preclinical studies by Q2 2021.

Mindset Pharma Logo
Discovery

EntheogeniX

EntheogeniX's drug pipeline or intended indications are unclear thus far.

EntheogeniX
Discovery

PsyBio

PsyBio is developing a portfolio of tryptamine-derived candidates including psilocybin and norbaeocystin for a variety of undisclosed psychiatric conditions.

PsyBio Logo
Discovery

Suggestions & Comments

Psilocybin Alpha reserves its right to exercise editorial judgement regarding the inclusion of drug development projects on this page, and does not claim that this resource is definitive. As with all of our resources, this should not inform investment decisions.

If you would like to suggest an addition or amendment to this Psychedelics Drugs Development Tracker, you are welcome to contact us at industry@psilocybinalpha.com